Ignite Creation Date:
2025-12-24 @ 3:34 PM
Ignite Modification Date:
2026-01-29 @ 8:05 PM
Study NCT ID:
NCT02169492
Status:
COMPLETED
Last Update Posted:
2017-08-07
First Post:
2014-06-13
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluation of the ReVive SE Device for Intra-Arterial Thrombectomy in Acute Ischemic Stroke
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D020521', 'term': 'Stroke'}], 'ancestors': [{'id': 'D002561', 'term': 'Cerebrovascular Disorders'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'OTHER'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 103}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2015-01-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2017-08', 'completionDateStruct': {'date': '2017-05-31', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2017-08-04', 'studyFirstSubmitDate': '2014-06-13', 'studyFirstSubmitQcDate': '2014-06-19', 'lastUpdatePostDateStruct': {'date': '2017-08-07', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2014-06-23', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2017-05-31', 'type': 'ACTUAL'}}, 'outcomesModule': {'otherOutcomes': [{'measure': 'emboli occurence', 'timeFrame': '90'}, {'measure': 'symptomatic intracranial hemorrhage (sICH)', 'timeFrame': '90 days'}, {'measure': 'Mortality', 'timeFrame': '90 days'}], 'primaryOutcomes': [{'measure': 'modified Rankin Scale', 'timeFrame': '90 days', 'description': 'Functional Independence of subjects as defined by modified Rankin Scale (mRS) ≤2 at 90 days post-procedure.'}], 'secondaryOutcomes': [{'measure': 'National Institute of Health Stroke Scale (NIHSS)', 'timeFrame': '90 days'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Thrombectomy', 'Stroke', 'ReVive SE'], 'conditions': ['Stroke']}, 'descriptionModule': {'briefSummary': 'The main objective of this study is to assess the safety and effectiveness of the ReVive SE (Self- Expanding) Neurothrombectomy Device in subjects requiring mechanical thrombectomy when used according to its Instruction for use (IFU).'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'subjects requiring mechanical thrombectomy', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. Clinical signs consistent with acute ischemic stroke\n3. No pre-stroke functional dependence (pre-stroke Modified Rankin Score ≤ 1)\n4. NIHSS ≥ 6,, assessed within two hours before treatment with ReVive SE\n5. Large (≥ 1.5mm) and proximal vessel occlusion (presenting TICI score of 0 or 1) of MCA (M1-M2), dICA, or BA confirmed by CT/MR angiography that it is accessible to the ReVive SE.\n6. Treatment initiated within 8 hours after symptom onset (first ReVive SE pass made within 6 hours\n7. Subject or legally authorized representative has provided informed consent on data collection, and consent is documented\n\nExclusion Criteria:\n\n1. Life expectancy of less than 90 days\n2. Neurological signs that are rapidly improving prior to or at time of treatment (NIHSS improves at least 4 points between subject presentation and treatment initiation)\n3. Subject is either exhibiting clinical signs suggestive of, or there is angiographic evidence of bilateral stroke\n4. Prior use of any other mechanical device to treat this stroke (e.g., Merci Retriever, Penumbra, Solitaire, Trevo, Mindframe, Phenox, stent)\n5. Known bleeding diathesis:\n\n 1. Current use of oral anticoagulants (eg, warfarin sodium) with International Normalized Ratio (INR) \\> 3;\n 2. Administration of heparin or Novel Oral AntiCoagulants (NOAC, eg Dabigatran, Rivaroxaban) within 48 hours preceding the onset of stroke and have an abnormal activated partial thromboplastin time (aPTT) at presentation; and/or\n 3. Platelet count \\< 100,000/mm3\n6. Glucose \\<50 mg/dL (2.8 mmol, 2.6mM)\n7. Uncontrolled hypertension (SBP\\>185 or DBP\\>110) refractory to pharmacological management\n8. Known hypersensitivity or allergy to nitinol and/or radiographic contrast agents\n9. Pregnancy or lactating female\n10. Subject already enrolled in a clinical study involving experimental medication or device\n\n Imaging Exclusion criteria:\n11. CT scan or MRI with evidence of acute intracranial hemorrhage, mass effect and/or intracranial tumor.\n12. Angiographic evidence of carotid dissection, or high grade stenosis (\\> 50% stenosis of the artery proximal to the target vessel) that will prevent access to the clot, or cerebral vasculitis\n13. Blood vessel with extreme tortuosity or other conditions preventing the access of the device.'}, 'identificationModule': {'nctId': 'NCT02169492', 'acronym': 'Re-ACT', 'briefTitle': 'Evaluation of the ReVive SE Device for Intra-Arterial Thrombectomy in Acute Ischemic Stroke', 'organization': {'class': 'INDUSTRY', 'fullName': 'Codman & Shurtleff'}, 'officialTitle': 'Evaluation of the ReVive SE Device for Intra-Arterial Thrombectomy in Acute Ischemic Stroke: An Observational, Prospective and Multicenter Study', 'orgStudyIdInfo': {'id': 'NV-PMK-1203'}}, 'contactsLocationsModule': {'locations': [{'city': 'Bordeaux', 'country': 'France', 'facility': 'CHU Bordeaux', 'geoPoint': {'lat': 44.84124, 'lon': -0.58046}}, {'city': 'Clermont-Ferrand', 'country': 'France', 'facility': 'CHU Clermont Ferrand', 'geoPoint': {'lat': 45.77969, 'lon': 3.08682}}, {'city': 'Colmar', 'country': 'France', 'facility': 'CHU de Colmar', 'geoPoint': {'lat': 48.08078, 'lon': 7.35584}}, {'city': 'Dijon', 'country': 'France', 'facility': 'CHU Dijon', 'geoPoint': {'lat': 47.31344, 'lon': 5.01391}}, {'city': 'Lille', 'country': 'France', 'facility': 'CHU Lille', 'geoPoint': {'lat': 50.63391, 'lon': 3.05512}}, {'city': 'Marseille', 'country': 'France', 'facility': 'CHU La Timone', 'geoPoint': {'lat': 43.29695, 'lon': 5.38107}}, {'city': 'Saint-Etienne', 'country': 'France', 'facility': 'CHU St Etienne', 'geoPoint': {'lat': 45.43389, 'lon': 4.39}}, {'city': 'Tours', 'country': 'France', 'facility': 'Hôpital Bretonneau', 'geoPoint': {'lat': 47.39484, 'lon': 0.70398}}], 'overallOfficials': [{'name': 'Benjamin Hoehn, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Codman Neuro'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Codman & Shurtleff', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}